Survival Outcome of EGFR-TKI in Uncommon EGFR Mutant Advanced NSCLC

Hunan Province Tumor Hospital

Status: Enrolling

Conditions: Non-small Cell Lung Cancer

Treatments: Drug: Third-generation EGFR-TKI; Drug: EGFR-TKI

Study type: Observational

Funder types: Other

Identifiers

NCT04324164

SONICS

Details and patient eligibility

About

This study aims to explore Survival Outcome of EGFR-TKI in Uncommon EGFR Mutant Advanced Non-small Cell Lung Cancer in China

Full description

inclusion criteria Uncommon EGFR Mutant Advanced Non-small Cell Lung Cancer EGFR G719X, exon 20 insert mutation without any anti-cancer treatment history

Enrollment: 800 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• 18，Advanced Non-squamous Non-small Cell Lung Cancer Confirmed by Histopathology

  • Uncommon EGFR Mutant Advanced NSCLC

Exclusion criteria

• Patients with contraindication of chemotherapy
• Pregnant or breast feeding women

Trial design

800 participants in 7 patient groups

Cohort 1 Uncommon EGFR exon 19del

Description:

patients with uncommon EGFR exon 19del

Treatment:

Drug: Third-generation EGFR-TKI

Cohort 2 EGFR exon 19delins

Description:

patients with EGFR exon 19delins

Treatment:

Drug: Third-generation EGFR-TKI

Cohort 3 EGFR exon 18del

Description:

patients with EGFR exon 18del

Treatment:

Drug: EGFR-TKI

Cohort 4 Common Uncommon Point Mutations

Description:

patients with common uncommon point mutations

Treatment:

Drug: EGFR-TKI

Cohort 5 Rare Uncommon Point Mutations

Description:

patients with rare uncommon point mutations

Treatment:

Drug: EGFR-TKI

Cohort 6 Compound Mutations Uncommon With Uncommon

Description:

patients with compound mutations uncommon with uncommon

Treatment:

Drug: EGFR-TKI

Cohort 7 Compound Mutations Uncommon With Common

Description:

patients with compound mutations uncommon with common

Treatment:

Drug: EGFR-TKI